NextCure (NXTC) SEC Filings: History & Chart

NextCure, Inc.(NXTC)

Biotechnology · Beltsville, MD

$5.69+0.63 (+12.57%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

Beltsville, MD

40 employees

www.nextcure.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael S. Richman

View full financials

Form	Filing Date	Accepted	Document
S-4/A	Oct 1, 2026	Sep 30, 2026	View filing
425	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 3, 2026	Sep 3, 2026	View filing
S-4	Aug 18, 2026	Aug 18, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
SC 13G	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
425	Aug 10, 2026	Aug 10, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
425	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 3, 2026	Aug 3, 2026	View filing
4	Jul 29, 2026	Jul 29, 2026	View filing
3	Jul 29, 2026	Jul 29, 2026	View filing
425	Jul 16, 2026	Jul 16, 2026	View filing
425	Jul 14, 2026	Jul 14, 2026	View filing
8-K	Jul 14, 2026	Jul 14, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 1, 2026	Jun 1, 2026	View filing
SC 13G/A	May 13, 2026	May 13, 2026	View filing

SEC Filings

Recent Filings